bearish
Global Cord Blood (CO US): No Immediate Respite Is Seen
177 Views30 Jan 2022 21:25
SUMMARY
- Global Cord Blood (CO US) has rejected the acquisition offer from Alternate Ocean Investment as it fails to properly reflect the value of the company and maximize shareholder value.
- Global Cord shares plunged 4% since we published our bearish view in late November. The shares are trading more than 35% below its 52-week high price.
- Although we are not seeing any upside potential, we have analyzed some key catalysts, which can move the share price higher.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Global Cord Blood (CO US): Fate Seems to Be Changing as New Growth Engine Added30 Apr 2022
- Global Cord Blood (CO US): Gloomy Regulatory and Business Environment Explain Cheap Valuation08 Apr 2022
- Global Cord Blood (CO US): No Immediate Respite Is Seen30 Jan 2022
- Global Cord Blood (CO US): Overhangs Persist; Weak Q2 Results Adds to Woe26 Nov 2021
- Global Cord Blood: Haitong Raids The Bank16 Mar 2021
x